Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises on Medivir’s new issue
Mandate

Vinge advises on Medivir’s new issue

March 29, 2010

Medivir AB (publ) (NASDAQ OMX Stockholm) is performing a rights issue for approximately SEK 300 million. The new issue is fully covered by subscription undertakings, declarations of intent and underwriting undertakings from, among others, Carnegie and Jefferies acting as Joint Bookrunners.

Vinge is advising Medivir. Vinge’s team consists of Erik Sjöman, Emil Hedberg and Jesper Schönbeck. In addition, Rikard Stenberg, Maria Doeser and Markus Larsson have been involved in the transaction.

Related

Vinge advises Consolid Equity in connection with the establishment of Petra Group

 Vinge has advised Consolid Equity Investment AB ("Consolid Equity") on the acquisition of Ström & Gulliksson, one of the leading patent agencies in the Nordics. The acquisition forms part of the establishment of Petra Group, a European platform aimed at consolidating patent agencies across Europe to combine expertise and resources primarily within patents and trademarks. Consolid acts as a strategic partner in the new group.
July 08, 2026

Vinge has advised Scandic on new credit facilities with SEK 7.5 billion credit facilities

 Vinge has represented Scandic Hotels Group AB (publ) in connection with a facilities agreement for SEK 7,500,000,000 with a syndicate of banks, arranged by DNB Carnegie Investment Bank AB and Nordea Bank Abp, filial i Sverige.
July 08, 2026

Vinge has advised Vitamin Well and its majority shareholders Cinven, Bridgepoint and the founders on Vitamin Well's combination with EMPWR

 Vinge has advised Vitamin Well and its majority shareholders Cinven, the founders of Vitamin Well and Bridgepoint on Vitamin Well's acquisition of EMPWR Nutrition Group from majority seller Waterland Private Equity Investments.
July 03, 2026